Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

British Journal of Cancer

Volumn 91, Issue 12, 2004, Pages 2012-2017

  Ring, A E ^a   Smith, I E ^a   Ashley, S ^a   Fulford, L G ^a   Lakhani, S R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Neoadjuvant chemotherapy; Oestrogen receptor; Pathological response

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; METHOTREXATE; MITOXANTRONE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DATA BASE; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PATHOGENESIS; PATHOLOGICAL COMPLETE RESPONSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 12344277756     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602235     Document Type: Article

References (28)

1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100
2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi C, Zucali R, Rilke F (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545
3. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNesse M, Strom E, Hunt K, Ames F, Hortobagyi GN (1999) Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17: 3412-3417
4. Buzdar AU, Valero V, Theriault R, Frye D, Green M, Booser D, Guerra L, Sahin A, Ames F, Smith T, Singletary E, Hortobagyi GN (2003) Pathological complete response (pCR) to chemotherapy is related to hormone receptor status. 26th San Antonio Breast Cancer Symposium, abstract 302
5. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A (2000a) Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 18: 584-590
6. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A (2000b) Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11: 1057-1059
7. Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, Jewell WR (2002) A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 184: 322-324
8. Detre S, Salter J, Barnes DM, Riddler S, Hills M, Johnston SR, Gillett C, A'Hern R, Dowsett M (1999) Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. Int J Cancer 81: 309-313
9. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942
10. Euler U, Tulusan AH (2003) An attempt to identify biological markers predicting response to primary chemotherapy with epirubicin/cyclophosphamide in locally advanced breast cancer. Proceedings of the American Society of Clinical Oncology 2003, abstract 3569
11. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685
12. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95: 681-695
13. Haagensen CD, Stout AP (1943) Carcinoma of the breast: criteria of operability. Ann Surgery 118: 859-870
14. Harris GC, Denley HE, Pinder SE, Lee AH, Ellis IO, Elston CW, Evans A (2003) Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol 27: 11-15
15. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481
16. Jacobs TW, Siziopikou KP, Prioleau JE, Raza S, Baum JK, Hayes DF, Schmitt SJ (1998) Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol 11: 259-264
17. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
18. Kaufmann M, Klinga K, Runnebaum B, Kubli F (1980) In vitro adriamycin sensitivity test and hormonal receptors in primary breast cancer. Eur J Cancer 16: 1609-1613
19. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNesse MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469
20. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre GM (1996) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465
21. Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single center. Ann Oncol 2: 347-354
22. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples. Br J Cancer 35: 1-39
23. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552
24. Ring A, Webb A, Ashley S, Allum WH, Ebbs S, Gui G, Sacks NP, Walsh G, Smith IE (2003) Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol 21: 4540-4545
25. Rosner D, Lane WW, Nemoto T (1989) Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study. Cancer 64: 6-15
26. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652
27. Smith IE, Lipton L (2001) Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2: 561-570
28. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237